Andrology · 2026
Male Sexual and Reproductive Health in Diabetes and Obesity Pharmacotherapy: A Source-Triangulated Counseling Map.
СтатьяОбзорНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Broul Marek, Dubský Michal, Hujová Aneta, Liegertová Michaela
Аннотация
BACKGROUND: Drugs used for diabetes and obesity increasingly shape male sexual and reproductive counseling, but clinical studies, trial registrations, regulatory labels, and patents answer different questions.
OBJECTIVES: The objective is to map these sources and define what each can support when counseling men receiving metabolic drugs.
MATERIALS AND METHODS: We reviewed human studies, ClinicalTrials.gov records, FDA/EMA labels, and selected patent or pipeline documents using source-specific eligibility criteria and evidence rules.
RESULTS: Human evidence is concentrated around glucagon-like peptide-1 receptor agonists (GLP-1 RAs), dual GLP-1/GIP receptor agonism, SGLT2 inhibitors, and metformin or paternal exposure. Direct fertility and live-birth data remain sparse. Trial registries include more male reproductive endpoints than published studies report. Regulatory labels mainly inform genital-safety counseling and nonclinical reproductive toxicology language. Patents contain erectile and male reproductive claims, but these claims are not clinical evidence.
DISCUSSION AND CONCLUSION: Counseling should separate genital safety, endocrine and sexual-function signals, semen and fertility outcomes, and paternal-exposure concerns. Hormonal, sexual-function, or semen changes may track metabolic recovery; they do not establish improved conception or live birth. These drugs should be selected for metabolic indications, not as treatments for ED or infertility.
OBJECTIVES: The objective is to map these sources and define what each can support when counseling men receiving metabolic drugs.
MATERIALS AND METHODS: We reviewed human studies, ClinicalTrials.gov records, FDA/EMA labels, and selected patent or pipeline documents using source-specific eligibility criteria and evidence rules.
RESULTS: Human evidence is concentrated around glucagon-like peptide-1 receptor agonists (GLP-1 RAs), dual GLP-1/GIP receptor agonism, SGLT2 inhibitors, and metformin or paternal exposure. Direct fertility and live-birth data remain sparse. Trial registries include more male reproductive endpoints than published studies report. Regulatory labels mainly inform genital-safety counseling and nonclinical reproductive toxicology language. Patents contain erectile and male reproductive claims, but these claims are not clinical evidence.
DISCUSSION AND CONCLUSION: Counseling should separate genital safety, endocrine and sexual-function signals, semen and fertility outcomes, and paternal-exposure concerns. Hormonal, sexual-function, or semen changes may track metabolic recovery; they do not establish improved conception or live birth. These drugs should be selected for metabolic indications, not as treatments for ED or infertility.